Measure size and number of embryoid bodies and patient-derived organoids
- Directly image tumor spheroids in various microwell formats
- Non-invasive brightfield imaging allows the user to image the same plate over multiple days
- Perform a two-color fluorescence viability assay
Introduction
The Celigo™ image cytometer has been developed to fully automate live cell analysis of tumorspheres. This automated morphometric analysis tool significantly reduces the time and effort needed to quantify key aspects of 3D spheres including size, growth, growth tracking over time, and response to chemotherapeutics.
Identification and counting of embryoid bodies from spinner flask
Experiment 1 procedure:
- One mL of cultured embryoid bodies was removed from a 250 mL spinner flask and plated onto a 24 well plate
- The embryoid bodies were analyzed for number and average diameter
Number of EBs | Avg. Diameter | SD Diameter | Min Diameter | Max Diameter | |
---|---|---|---|---|---|
Celigo | 643 | 187.1 microns | 63.9 microns | 82.5 microns | 514.6 microns |
Manual Count | 81 | 200 microns | 61.2 microns | 99.6 microns | 434.4 microns |
- A gate was set to show the software identification of embryoid bodies sizes.
- In this example, the red EBs have an average area of 11,577 square microns compared to the green embryoid bodies that have an average area of 38,196 square microns.
- Also, this distribution shows that most embryoid bodies fall within 10 – 50k square microns with very few very large embryoid bodies that are 100k or more.
- In this example, the size gate was set at 120 microns. Therefore, all EBs circled in red have a diameter of less than 120 microns (which is 181 EBs)
- All EBs circled in blue are larger than 120 microns and are 462 in number
Experiment 2 Procedure: Identification and counting of embryoid bodies
- Whole well images from a 6-well plate were acquired and analyzed.
- Below are representative raw and analyzed images of the forming embryoid bodies.
- Green outline indicates counted stem cell aggregates.
Size gating
EBs | Number | Min size (µM) | Max size (µM) | Avg size (µM) | STDEV |
---|---|---|---|---|---|
Total | 3362 | 51.9 | 517.8 | 96.5 | 40.8 |
Small | 1181 | 51.9 | 75.1 | 63.9 | 6.7 |
Medium | 1863 | 75.0 | 149.0 | 100.47 | 19.0 |
Large | 323 | 149.3 | 517.8 | 191.9 | 44.8 |
Cell sources for generation of patient-derived organoids (PDOs)
- PDO’s generated from 6000 mouse pancreatic cells seeded in Matrigel™ and imaged 3-day post seeding.
- Whole well brightfield images were acquired and organoid sizes automatically determined by the Celigo software.
- Green fill pseudo-color is used to easily identify the Celigo counted PDOs.
- PDO’s generated from 2000 mouse pancreatic cells seeded in Matrigel™ and imaged 3-day post seeding.
- Whole well brightfield images were acquired and organoid sizes automatically determined by the Celigo software.
- Green fill pseudo-color is used to easily identify the Celigo counted PDOs.
- PDO’s generated from 2000 mouse pancreatic cells seeded in Matrigel™ and imaged 3-day post seeding.
- Whole well brightfield images were acquired and organoid sizes automatically determined by the Celigo software. The inset shows a zoomed in brightfield image.
- The Celigo software was used to generate the whole well RFP and brightfield overlay image.
- PDO’s generated from 500 mouse pancreatic cells seeded in Matrigel™ and imaged 3-day post seeding.
- Whole well brightfield images were acquired and organoid sizes automatically determined by the Celigo software.
- Green fill pseudo-color is used to easily identify the Celigo counted PDOs.
For research use only. Not for use in diagnostic procedures.
Disclaimer: The mention of Matrigel™, an extracellular matrix, in this collateral is for informational purposes only, reflecting the specific materials used in our research. The inclusion of this product’s name is solely to provide for the accuracy and reproducibility of the research described herein. Matrigel™ is a trademark of Corning, Inc., which has not endorsed, funded, or otherwise participated in the study described herein, and there is no affiliation between Revvity and the aforementioned company.